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BACKGROUND: Breast cancer relative survival (BCRS), which compares the observed survival of women with breast cancer with the
expected survival of women for the whole population of the same age, time period, and geographical region, tends to be poorer in
older women, but the reasons for this are not clear. We examined the influence of patient and tumour characteristics, and treatment
on BCRS to see whether these could explain the age-specific effect.
METHODS: Data for 14048 female breast cancer patients diagnosed from 1999 to 2007, aged 50 years or over were obtained from
the Eastern Cancer Registration and Information Centre. We estimated relative 5- and 10-year survival for patients in four age groups
(50–69, 70–74, 75–79, and 80þ years). We also modelled relative excess mortality (REM) rate using Poisson regression adjusting
for patient characteristics and treatment. The REMs derived from these models quantify the extent to which the hazard of death
differs from the hazard in the reference category, after taking into account the background risk of death in the general population.
We compared the results with those obtained for breast cancer-specific mortality, analysed using multivariate Cox regression.
RESULTS: Median follow-up time was 4.7 years. Relative 5-year survival was 89, 81, 76, and 70% for patients aged 50–69, 70–74,
75–79, and 80þ years, respectively. Corresponding relative 10-year survival was 84, 77, 67, and 66%. Unadjusted REM was 1.93,
2.74, and 3.88 for patients aged 70–74, 75–79, and 80þ years, respectively, (50–69 years as reference). The equivalent hazard
ratios from the Cox model were 1.88, 2.45, and 3.81. These were attenuated after adjusting for confounders (REM – 1.49, 1.36, and
1.23; Cox – 1.47, 1.50, and 1.76).
CONCLUSION: We confirmed poorer BCRS in older women in our region. This was partially explained by known prognostic factors.
Further research is needed to determine whether biological differences or suboptimal management can explain the residual excess
mortality.
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In the United Kingdom, breast cancer accounts for 31% of
all cancers in women (Cancer Research UK, 2010). Of these,
almost a third occur in women aged X70 years (Cancer screening
programme, 2009). Patient characteristics, tumour characteristics,
and treatment all influence prognosis in women diagnosed with
breast cancer. Tumour characteristics that are major determinants
of prognosis are lymph node status, tumour size, histopathological
grade, and oestrogen receptor (ER) status (Puglisi et al, 1999).
Important patient characteristics include age at diagnosis and
presence of significant comorbidity (Janssen-Heijnen et al, 2005).
The relationship between age, patient characteristics, treatment,
and prognosis in women with breast cancer is complex. For
example, older women tend to present with later-stage disease but
are more likely to have suboptimal management, and are more
likely to die from comorbid conditions (Diab et al, 2000; Eaker
et al, 2006). Despite this, it is clear that relative survival in older
patents is poorer than that of younger patients (Eaker et al, 2006;
Cancer screening programme, 2009). The reasons for the poorer
prognosis in older patients are not clear.
Suboptimal management might also be important. Wishart et al
(2010) showed that age-specific variation in treatment, particularly
in the use of adjuvant hormone and chemotherapy might be
attributed to lack of information in older women, in particular
nodal status and ER status. The same study also documented that
women 470 years of age, who had surgery as part of their
treatment, had better overall survival. Several reports have shown
that less aggressive patterns of diagnostic activity and care are
provided to elderly breast carcinoma patients (Hebert-Croteau
et al, 1999; Woodard et al, 2003), but the impact of these
differences on breast cancer survival remains controversial. Gajdos
et al (2001) found that rates of recurrence were not increased when
undertreated women (older than 70 years) were compared with
conventionally treated patients, whereas others have found that
undertreatment is associated with recurrence and decreased
survival (Bouchardy et al, 2003).
Variations in care given, and hence prognosis in old patients
may be due in part to lack of published guidelines for diagnosis
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sand treatment. This in turn is partly caused by the fact that few
randomised controlled trials (RCTs) of breast cancer treatments
have included women X70 years old, and most observational
studies have been limited by small sample sizes in this age group
(Hebert-Croteau et al, 1999; Gajdos et al, 2001; Bouchardy et al,
2003). Recently Schonberg et al (2010) have shown that old women
have breast cancer characteristics similar to those of younger
women, yet receive less aggressive treatment. They suggested that
further studies focusing on identifying tumour and patient
characteristics are required, which would help target treatments
to the oldest women who are most likely to benefit.
The unfavourable breast cancer survival in old women is even
more prominent in the UK compared with its counterparts in
many other equally developed countries (US, Sweden, Norway, and
Australia) (Woods et al, 2009; Moller et al, 2010). Some studies
suggested that a large proportion of differences in survival between
the UK and other developed countries can be attributed to
differences in stage at diagnosis (Sant et al, 2001, 2003).
The aim of this study was to estimate age-specific relative
survival in women with breast cancer from the eastern region of
England and to explore factors that might explain differences. We
also compared the results of the relative survival analyses with the
results from an analysis of breast cancer-specific mortality.
PATIENTS AND METHODS
Patient data
We used cancer registration data from the Eastern Cancer
Registration and Information Centre (ECRIC). All women aged
X50 years and diagnosed from 1999 to 2007 with invasive breast
cancer (ICD10-site code C50) were eligible for inclusion. During
this period, ECRIC covered a population of 2.7 million people in
the counties of Bedfordshire, Cambridgeshire, Norfolk, and
Suffolk. Cases diagnosed at autopsy or ascertained from death
certificate only (DCO) were excluded from the analysis. Eastern
Cancer Registration and Information Centre routinely collects data
on tumour size, lymph nodes involved, histopathological grade, ER
status, mode of detection (screen detected or symptomatic),
hospital of diagnosis, and treatment modalities. Patient follow-up
is carried out through death certification by the National Health
Service Strategic Tracing Service.
Cases in which women were diagnosed with bilateral synchro-
nous breast cancers, data for the most advanced tumour were used
in the analysis. In women with metachronous tumours, only the
data relating to the first diagnosis were used. Women who had a
previous diagnosis of another cancer were excluded. These patients
were excluded because survival might be influenced by the
previous cancer. This is a standard practice in the population-
based survival analysis and has been used previously in many
studies (Berrino et al, 1998; Capocaccia et al, 2003).
The primary sources of registration and treatment data are
reports obtained from all pathology laboratories and hospital
patient notes from all major NHS hospitals in the region. These are
viewed by registry staff, who are either based at the hospital or visit
them at least on a monthly basis. Both electronic and paper-based
reports are received by the registry, so a high level of completeness
of registration is expected. Quality controls included routine
plausibility checks on diagnosis, morphology, topography, age,
dates, and check on completeness, as well as controls on
compatibility of the variables used for staging.
Tumour stage was coded using the TNM classification system
for disease stage at the time of diagnosis (Sobin and Wittekind,
1997). The grouped TNM stage in this data included the
pathological stage group, augmented by the clinical stage group
when the pathological stage was not recorded. The histopatho-
logical grade is the degree of differentiation. Cases described as
‘well differentiated’ were assigned as grade 1; ‘moderately differen-
tiated’ as grade 2; ‘poorly differentiated and undifferentiated’ as
grade 3, and ‘ungraded (including grade Gx and missing data),’
grade unknown. Volume of treatment at hospital of diagnosis
during the study period was categorised as high (465 patients or
more throughout the study period) or low (less than 465 patients)
throughout the study period. Treatment was classified using
indicator variables (yes/no) for surgery, adjuvant chemotherapy,
adjuvant radiotherapy, and adjuvant hormonal therapy.
The measure of deprivation used by the UK Association of
Cancer Registries in cancer survival analysis is the income domain
score of The Index of Multiple Deprivation (IMD, 2004) for each
lower level super output area of residence. These scores are
grouped into fifths, based on their rankings for the whole of
England. The IMD is a standard measure of deprivation at small
area level across England. The IMD is based on seven domains –
income, employment, health and disability, education and skills,
barriers to housing and services, living environment, and crime.
Each domain in turn is based on a number of indicators, with some
domains also split into subdomains. The full data sets include
scores and ranks at small area level for the IMD, domains (and
subdomains), individual indicators, and population denominators
(The English Indices of Deprivation 2004: Summary (revised),
2010).
For the analyses of breast cancer-specific mortality, a death was
assumed to be from breast cancer in which breast cancer was
recorded as a cause of death in part 1 of the death certificate.
Statistical methods
Survival time was measured from the patient’s date of diagnosis
until death or 30 November 2009, whichever came first. To allow
for any delay in death notification, ascertainment of vital status
was as of 31 May 2010.
We estimated the relative 5- and 10-year survival rate for
patients in four age groups (50–69, 70–74, 75–79, and 80þ
years). The relative survival rate (RSR) is an analogue of excess
mortality and is a commonly used measure for analysing the
survival of cancer patients in population studies, in which cancer-
specific mortality might be inadequately ascertained. RSRs adjust
all-cause mortality for competing causes of death that would be
expected for persons of the same age and sex, time period, and
geographic region as the breast cancer patients in the study,
without requiring information on the actual cause of death of each
patient. Relative survival analysis was performed in Stata using the
strs command. The expected survival rates were derived using
single year of age and sex-specific death rates from the East of
England life tables.
To study differences in survival between different age groups,
while adjusting for the confounding factors available in the data
set, we modelled relative excess mortality (REM) using Poisson
regression (Dickman et al, 2004). The REMs derived from these
models quantify the extent to which the hazard of death differs
from the hazard in the reference category, after taking into account
the background risk of death in the general population. We chose
women aged 50–69 years as a reference group, as we found little
evidence for differences in relative survival within this age group
(data not shown). In addition, women aged 50–69 years are
eligible for mammography screening under the NHS breast
screening programme, and treatment protocols for this age group
are reasonably well defined.
The prognostic importance of age, TNM stage, histopathological
grade, ER status, mode of detection, deprivation quintile, volume
at hospital of diagnosis, and treatment was analysed by both uni-
and multivariate-relative survival models. The multivariate analy-
sis was undertaken by taking into consideration all the prognostic
factors examined in univariate analysis. Different interactions were
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deviance or the likelihood ratio test.
Finally, we compared the results with those obtained for
breast cancer-specific mortality analysed using multivariate Cox
regression.
We had some missing data on three of the variables included in
the analyses, namely stage at diagnosis, histopathological grade,
and ER status. We therefore analysed our data using two different
approaches. First, we used the standard method, which is the
complete case analysis (CCA), in which patients with missing data
are excluded. In addition, we reanalysed our data using multiple
imputation (MI), in which missing data are predicted using
existing values from other variables (White et al, 2009). We used
the same approach that we used in one of our studies (Ali et al,
which has been accepted by the British Journal of Cancer
‘MD/2010/3317R’). We included all the other variables in the
imputation model, in addition to the outcome of interest (overall
mortality in REM models and breast-specific mortality in Cox
regression models).
The results of CCA and MI were similar. We therefore reported
the results of the CCA in the main manuscript and the results
from the MI in the Supplementary Tables 1 and 2.
It is to be noted that, from the likelihood ratio tests, stage at
diagnosis was better to be treated as a categorical variable in the
REM analyses and as a continuous variable in Cox regression
analyses. We reported the results of the same models, which
included stage as a continuous variable, in both analyses for
comparative purposes. We have shown the results of the model,
which included stage as a categorical variable, in the Supplemen-
tary Table 3.
RESULTS
Description of the data set
We identified 14048 cases of invasive female breast cancer, of
which 97% were confirmed histologically. Of the 14048 patients
included in our final study population, almost 40% were X70
years. Table 1 summarises the clinical and tumour characteristics
by age at diagnosis. There were large age-specific differences in
almost all the variables of interest, with older women being more
likely to be associated with poor prognostic factors. For example,
50% of patients aged 50–69 years were screen detected compared
with 6% in patients aged 75–79 years, and 1% in patients aged
X80 years old. Older women were less likely to have had lymph
nodes examined and were more likely to be diagnosed with late-
stage disease. Older patients were less likely to be treated with
surgery and to get local and systemic adjuvant therapies apart
from adjuvant endocrine therapy, which was more commonly
prescribed in older patients. In addition, older women were less
likely to be treated with radiotherapy after breast-conserving
surgery.
Although our data were almost complete for most of the
variables, some data were missing for three of the variables
included in the analysis. Missing information was much more
frequent in old patients for these variables. About 30% of patients
aged X80 years old had data missing on at least one of the
variables analysed compared with 6% in women aged 50–69 years.
Among women who died, the proportion that died of breast
cancer relative to other causes declined from 70%, in women
diagnosed aged 50–69 years, to 39%, in women diagnosed aged
80 and over (Table 2).
Survival analysis
Over a median follow-up of 4.7 years (69834 person years), there
had been 4225 deaths in the 14048 patients. The overall 5- and
Table 1 Clinical and tumour characteristics by age group ((East
of England, 1999–2007)
Age at diagnosis (in years)
50–69 70–74 75–79 80+ Total
Factor N (%) N (%) N (%) N (%) N (%)
Number of patients 8514 1561 1487 2486 14048
Year of diagnosis
1999–2001 2559 (30) 538 (35) 525 (35) 823 (33) 4445 (32)
2002–2004 3047 (36) 554 (35) 484 (33) 838 (34) 4923 (35)
2005–2007 2908 (34) 469 (30) 478 (32) 825 (33) 4680 (33)
Stage at diagnosis
I 4285 (51) 565 (37) 426 (30) 539 (26) 5815 (43)
II 3439 (41) 724 (47) 697 (50) 1018 (48) 5878 (44)
III 387 (5) 110 (7) 142 (10) 338 (16) 977 (7)
IV 288 (3) 127 (8) 139 (10) 214 (10) 768 (6)
Unstaged 115 (1) 35 (2) 83 (6) 377 (15) 610 (4)
Tumour size (mm)
o20 4664 (60) 598 (44) 411 (34) 450 (27) 6123 (51)
20–49 2665 (35) 670 (49) 665 (55) 975 (59) 4975 (42)
50+ 386 (5) 102 (7) 126 (10) 227 (14) 841 (7)
Missing 799 (9) 191 (12) 285 (19) 834 (34) 2109 (15)
Lymph nodes
Negative 2512 (34) 434 (36) 392 (41) 355 (46) 3693 (36)
Positive 4822 (66) 756 (64) 560 (59) 409 (54) 6547 (64)
Missing 1180 (14) 371 (24) 535 (35) 1722 (69) 3808 (27)
Grade
1 1634 (20) 205 (15) 167 (14) 265 (17) 2271 (19)
2 4058 (51) 762 (55) 677 (56) 906 (57) 6403 (53)
3 2284 (29) 430 (31) 367 (30) 409 (26) 3490 (29)
Missing 538 (6) 164 (11) 276 (19) 906 (36) 1884 (13)
ER status
Negative 1181 (16) 182 (14) 165 (15) 202 (13) 1730 (15)
Positive 6383 (84) 1089 (86) 961 (85) 1407 (87) 9840 (85)
Missing 950 (11) 290 (19) 361 (24) 877 (35) 2478 (18)
Mode of detection
Screening 4278 (50) 294 (19) 94 (6) 27 (1) 9355 (67)
Clinical 4236 (50) 1267 (81) 1393 (94) 2459 (99) 4693 (33)
Nodes excised
o10 3925 (54) 637 (54) 462 (49) 415 (55) 5439 (53)
10–14 1710 (23) 291 (24) 279 (29) 183 (24) 2463 (24)
414 1698 (23) 262 (22) 210 (22) 163 (21) 2333 (23)
Missing 1181 (14) 371 (24) 536 (36) 1725 (69) 3813 (27)
Deprivation quintile
1 (Least deprived) 2086 (25) 343 (22) 294 (20) 416 (17) 3139 (22)
2 2424 (28) 417 (27) 391 (26) 681 (27) 3913 (28)
3 2193 (26) 418 (27) 421 (28) 711 (29) 3743 (27)
4 1308 (15) 277 (18) 260 (17) 480 (19) 2325 (17)
5 (Most deprived) 503 (6) 106 (7) 121 (8) 198 (8) 928 (7)
Hospital volume
High 7797 (92) 1465 (94) 1387 (93) 2222 (89) 12871 (92)
Low 717 (8) 96 (6) 100 (7) 264 (11) 1177 (8)
Surgery
Yes 8156 (96) 1328 (85) 1093 (74) 1051 (42) 11628 (83)
No 358 (4) 233 (15) 394 (27) 1435 (58) 2420 (17)
Radiotherapy
Yes 6321 (74) 1001 (64) 783 (53) 650 (26) 8755 (62)
No 2193 (26) 560 (36) 704 (47) 1836 (74) 5293 (38)
Chemotherapy
Yes 2502 (29) 104 (7) 50 (3) 26 (1) 2682 (19)
No 6012 (71) 1457 (93) 1437 (97) 2460 (99) 11366 (81)
Hormone therapy
Yes 5992 (70) 1211 (78) 1112 (75) 1903 (77) 10218 (73)
No 2522 (30) 350 (22) 375 (25) 583 (23) 3830 (27)
BCS
Yes 5543 (65) 772 (49) 515 (35) 506 (20) 7336 (52)
No 2971 (35) 789 (51) 972 (65) 1980 (80) 6712 (48)
BCS+radiotherapy
Yes 4864 (77) 673 (67) 437 (56) 348 (54) 6322 (72)
No 1457 (23) 328 (33) 346 (44) 302 (46) 2433 (28)
Abbreviations: BCS¼breast-conserving surgery; ER¼oestrogen receptor.
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s10-year RSRs were 84% (95% CI: 83–85%) and 78% (95% CI:
77–80%), respectively. As expected, given their clinical charac-
teristics, older patients had the poorest 5- and 10-year prognosis,
whereas patients diagnosed at ages 50–69 years experienced the
best survival (Figure 1). RSR by other patient, tumour, and
treatment characteristics are shown in Table 3.
We used REM to model the effect of age at diagnosis adjusted
for other prognostic variables (Table 4). Patients X70 years
old had significantly higher REM in comparison with the younger
age group (50–69 years) for all the models. Unadjusted REMs were
1.93 (95% CI: 1.64–2.26), 2.74 (95% CI: 2.35–3.20), and 3.88
(95% CI: 3.38–4.45) for patients aged 70–74, 75–79, and 80þ
years, respectively. We then adjusted the REM for other prognostic
covariates adding stage, grade, ER status, and surgery in turn
(models 2–5). Each additional variable resulted in some attenua-
tion of the age-specific REM. In the model, adjusted for all four
variables, the age-specific REM estimates were substantially
attenuated and the REM in the 80þ year age group was no
longer statistically significant. There was little difference between
the model 5 and a fully adjusted model that included stage, grade,
ER status, mode of detection, deprivation quintile, hospital
volume, year of diagnosis, and treatment (model 6).
The REM estimates for each variable included in the final model
are shown in Table 5. It is notable that relative survival was better
for patients treated in hospitals with a high volume (adjusted REM
¼0.69, 95% CI: 0.50–0.95). In addition, surgery was associated
with the greatest increase in relative survival (REM¼0.36, 95%
CI: 0.30–0.44) on multivariate analysis. The hazard ratio estimates
for both univariate and multivariate Cox regression using breast
cancer mortality as the end point were similar to the relative excess
mortality estimates. This suggests that the results of the relative
survival analysis are robust.
Table 5 shows that REM declines with age in the oldest age
groups, whereas breast cancer-related mortality increases with age
in the Cox models. This contradiction seems to be because of
missing data, because when we reanalysed our data using MI, this
observation is no longer apparent (Supplementary Table 2).
Table 2 Breast cancer mortality in relation to all causes of mortality
(follow-up period, 1999–2009)
Total deaths Deaths from breast cancer %
50–69 1334 933 70
70–74 514 293 57
75–79 696 329 47
X80 1681 663 39
Total 4225 2218 53
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Figure 1 Relative survival for females diagnosed with cancer of the
breast (East of England, 1999–2007).
Table 3 Relative 5- and 10-year survival of breast cancer patients
by patient, tumour, and treatment characteristics (East of England,
1999–2007)
5 years 10 years
N RSR (%) LCL UCL RSR (%) LCL UCL
Age group (in years)
50–69 8506 89 89 90 84 82 85
70–74 1556 81 78 84 77 71 82
75–79 1482 76 72 79 67 59 74
80+ 2451 70 66 74 66 55 78
Period
1999–2001 4417 72 83 82 77 75 79
2002–2004 4912 74 84 83 NA
a NA NA
2005–2007 4666 75 86 83 NA NA NA
Stage at diagnosis
I 5814 99 98 99 97 95 100
II 5877 87 85 88 79 76 81
III 975 48 44 52 29 22 37
IV 764 14 11 17 5 2 9
Grade
1 2271 99 97 100 98 94 100
2 6403 92 91 93 88 85 90
3 3490 74 72 76 67 64 70
ER status
Negative 1730 68 66 71 66 62 69
Positive 9840 91 90 92 86 84 87
Mode of detection
Screening 4693 97 96 97 95 93 97
Clinical 9302 78 76 79 70 68 72
Deprivation
1 (least deprived) 3127 87 85 89 82 79 85
2 3895 85 83 86 80 77 83
3 3736 82 80 84 76 72 79
4 2313 83 80 85 78 73 82
5 (Most deprived) 924 82 78 86 69 61 77
Hospital volume
High (465+ patients) 12858 85 84 86 79 77 80
Low (o465 patients) 1137 78 75 81 75 70 80
Surgery
Yes 11628 92 91 93 88 86 89
No 2367 39 36 42 21 16 26
Radiotherapy
Yes 8755 89 88 90 85 83 86
No 5240 75 74 77 67 63 70
Chemotherapy
Yes 2682 76 74 78 65 62 68
No 11313 86 85 87 82 80 84
Hormone therapy
Yes 10218 88 87 89 81 79 83
No 3777 74 73 76 70 68 73
Abbreviations: LCL¼95% lower confidence limit; N¼number of observations at the
beginning of follow-up; RSR¼relative survival rate; UCL¼95% upper confidence
limit.
aNA¼not applicable as the follow-up for these periods is less than 10 years.
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sDISCUSSION
We have used data from a population-based cancer registry
to investigate age-specific breast cancer relative survival (BCRS) in
the East of England. The clinical and tumour characteristics were
different in older women, and this was reflected in large differences
in relative survival and breast cancer-specific survival with survival
being poorer in older patients. These differences were substantially
reduced in a multivariate model. Some of the variables in this
model reflect differences in the care pathway between older and
younger patients, and other differences reflect variations in
underlying tumour biology. This suggests that it might be possible
to improve the prognosis in older patients by improving the
manner in which breast cancer is diagnosed and treated in this age
group. The results of this analysis are generally similar to those of
other studies (Diab et al, 2000; Grosclaude et al, 2001; Eaker et al,
2006; Schonberg et al, 2010). The presence of residual differences
in age-specific relative survival might be explained by either
biological differences and/or suboptimal management (Lavelle
et al, 2007; Schonberg et al, 2010). For example, it has been shown
that, increasing age is an independent risk factor for nonreceipt of
effective therapies after allowing for differences in tumour
characteristics (Enger et al, 2006; Lavelle et al, 2007).
We conducted two complementary survival analyses, relative
survival and breast cancer-specific survival. The similarity of the
results suggests that relative survival is a valid method for
evaluating survival time data. Its major advantages are that
information on cause of death is not required and that it provides a
measure of the excess mortality experienced by patients diagnosed
with cancer, irrespective of whether the excess mortality is directly
or indirectly attributable to the cancer (Dickman et al, 2004).
In addition, relative survival estimates the net survival, as,
by definition, it takes into account background mortality in
the general population of the same age, geographical area, and
time period.
We have confirmed the prognostic importance of stage at
diagnosis, tumour grade, and ER status, as well as the benefit of
surgery. Adjusting for stage had the biggest effect on age-specific
relative survival (models 1 and 2 in Table 4). The reasons for older
women presenting with late-stage disease are complex, but it is
partly due to the fact that eligibility for the NHS Breast Screening
Programme was restricted to women aged 50 to 69 years. Earlier
diagnosis in older women has the potential to improve prognosis.
In addition, there is good evidence that the higher proportion of
older women presenting with more advanced stages of breast
cancer is because of delay in seeking help (Ramirez et al, 1999).
These data also provide some evidence for suboptimal
diagnostic work up in older women who were less likely to have
had tumour ER status evaluated and were less likely to have had
axillary lymph nodes examined. This might have resulted in
Table 4 10-year relative excess mortality and 95% CIs for different age groups
50–69 years (reference)
70–74 years 75–79 years 80+ years
REM REM LCL UCL REM LCL UCL REM LCL UCL
Model 1 1 1.93 1.64 2.26 2.74 2.35 3.20 3.88 3.38 4.45
Model 2 1 1.37 1.18 1.60 1.62 1.39 1.89 1.92 1.67 2.21
Model 3 1 1.37 1.15 1.63 1.45 1.20 1.76 1.36 1.11 1.68
Model 4 1 1.50 1.24 1.81 1.49 1.21 1.84 1.47 1.17 1.84
Model 5 1 1.48 1.23 1.79 1.39 1.12 1.71 1.19 0.95 1.49
Model 6 1 1.49 1.22 1.82 1.36 1.09 1.70 1.23 0.97 1.58
Abbreviations: LCL¼95% lower confidence limit; REM¼relative excess mortality; UCL¼95% upper confidence limit.
Notes: Model 1, unadjusted; Model 2, adjusted for stage; Model 3, adjusted for stage, grade; Model 4, adjusted for stage, grade, ER status; Model 5, adjusted for stage, grade, ER
status, surgery; Model 6, adjusted for stage, grade, ER status, mode of detection, hospital volume, deprivation quintile, surgery, chemotherapy, radiotherapy, hormonal therapy,
and year of diagnosis.
Table 5 Estimated 10-year relative excess mortality and hazard ratio (univariate and multivariate) and their 95% CIs
REM Cox
Univariate Multivariate Univariate Multivariate
Variable REM LCL UCL HR LCL UCL HR LCL UCL HR LCL UCL
Age group (in years)
50–69 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
70–74 1.93 1.64 2.26 1.49 1.22 1.82 1.88 1.65 2.15 1.47 1.22 1.77
75–79 2.74 2.35 3.20 1.36 1.09 1.70 2.45 2.16 2.78 1.50 1.24 1.82
80+ 3.88 3.38 4.45 1.23 0.97 1.58 3.81 3.44 4.21 1.76 1.46 2.12
Period
a 0.93 0.86 1.00 0.88 0.80 0.96 0.91 0.86 0.96 0.90 0.83 0.97
Stage
a 4.57 4.32 4.84 3.12 2.85 3.41 4.05 3.87 4.23 2.95 2.73 3.18
Grade
a 3.73 3.21 4.32 2.26 1.97 2.59 2.83 2.60 3.08 2.09 1.87 2.33
ER positive 0.26 0.23 0.30 0.60 0.50 0.73 0.34 0.31 0.38 0.55 0.47 0.66
Screen detected 0.08 0.06 0.12 0.66 0.54 0.81 0.17 0.15 0.20 0.67 0.56 0.80
Deprivation quintile
a 1.12 1.07 1.17 1.08 1.02 1.14 1.13 1.09 1.16 1.06 1.01 1.11
High hospital volume 1.45 1.22 1.71 0.69 0.50 0.95 1.36 1.18 1.56 0.79 0.61 1.03
Surgery 0.07 0.06 0.08 0.36 0.30 0.44 0.12 0.11 0.14 0.39 0.32 0.46
Radiotherapy 0.34 0.30 0.38 0.85 0.73 0.98 0.55 0.50 0.60 1.05 0.92 1.20
Chemotherapy 1.78 1.60 1.98 1.10 0.93 1.29 1.69 1.54 1.86 1.21 1.04 1.41
Hormonotherapy 0.41 0.36 0.45 0.71 0.59 0.86 0.59 0.54 0.64 0.88 0.75 1.03
Abbreviations: CI¼confidence interval; HR¼Hazards ratio; LCL¼95% lower confidence limit; REM¼relative excess mortality; UCL¼95% upper confidence limit.
aThese variables were treated as continuous variables, giving hazard ratios per unit increase.
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sinappropriate use of adjuvant hormone replacement therapy or
suboptimal use of adjuvant chemotherapy. Further analysis of the
implications of missing data on age-specific survival may shed
more light on this issue. However, older persons are heterogeneous
with respect to functional reserve, comorbidity, and personal
preferences, all of which need to be considered in the treatment
decision-making process. In some cases, less intensive diagnostic
work up and treatment may have been appropriate. However,
comorbidity data were not available to evaluate its importance in
the care pathway decision making. Nevertheless, some studies have
found non-rational differences in treatment among older women
even after controlling for comorbidity (Giordano et al, 2005; Enger
et al, 2006).
We found that women from more deprived areas have a poorer
relative survival as has previously been observed by (Coleman
et al, 2001). Unadjusted REM was 57% higher in the patients
from the most deprived areas compared with those from the
most affluent areas. Even after adjustment for confounders the
excess was 36%. This raises an important issue in health policy
regarding socioeconomic inequalities in management of patients
with breast cancer.
Some researchers have argued that we do not need more
research to document what we already know – that older women
get suboptimal care (Mandelblatt, 2006). Instead, they stressed the
need for better understanding of the biology of cancer in this
population. However, our results, in concordance with others
(Diab et al, 2000), emphasise the lack of knowledge about how best
to manage older patients with breast cancer, and support the view
that the benefit of therapy in older women on the natural history
of the disease and the quality of life require evaluation in RCTs.
The strength of this study is its population-based case
ascertainment through cancer registry, minimising the potential
for selection bias as observed for hospital-based survival data and
for clinical studies. The results of our study are representative of
the whole population of the eastern region of England. Incomplete
registration or coding mistakes, which can bias the survival
estimates because of patient selection, is not a likely source of bias
in this study. Cases known to registries through death certificates
only (DCO) were excluded from the analysis. The proportion of
microscopically verified cases in this study is 97%. Eastern Cancer
Registration and Information Centre uses active follow-up, so
potential bias due to incomplete follow-up is less likely. Avoidance
of selection bias is the main reason to use a cancer registry-based
study, however, one form of selection bias may affect these survival
analyses if there are differences in assignment of patients to
treatment (Grosclaude et al, 2001). Selection of therapy depends
not only on the stage of the disease, but also on grade, endocrine
receptor status, general health, patient preferences, and so on.
These factors may have resulted in selection bias in this study.
Although missing data are of concern in the cancer registry data,
missing data are not likely to be a problem in our analysis because
we had a small proportion of cases that had missing information
on few variables. In addition, when we compared the results of
the CCA with the results from MI, the results were fundamentally
very similar.
In conclusion, we have shown that older women with breast
cancer have unfavourable clinical characteristics at presentation
and poorer relative survival. Some of the survival difference can be
explained by differences in the clinical characteristics by age,
including stage at presentation, tumour grade, and ER status, but
residual unexplained differences remain. This study has also
highlighted the importance of surgery, which also accounted for
some of the age-specific differences in survival. As a result, all
older patients should be considered for surgery if fit enough with
or without adjuvant radiotherapy and hormone therapy. Further
studies are also needed to ensure the inclusion of detailed
information on treatment and other factors such as comorbidity,
patient preferences, waiting time for diagnosis, and/or treatment.
Studies of currently available and potential molecular markers
might provide better insights into the tumour biology of breast
cancer in the elderly and reveal new opportunities for directing
anticancer strategies in this age group.
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